Nuvalent, INC

Nuvalent, Inc. has been acquired by GlaxoSmithKline LLC for approximately $10.6 billion in cash, with the merger officially closing on July 15, 2026.

Nuvalent, Inc. held its 2026 Annual Meeting of Stockholders, where directors were elected, executive compensation was approved, and the appointment of KPMG LLP as auditor was ratified.

GSK plc announced an agreement to acquire Nuvalent, Inc. for $10.6 billion, gaining a multi-product oncology portfolio including late-stage NSCLC treatments.

Nuvalent announced first quarter 2026 financial results, highlighting significant progress in its ROS1 and ALK programs with NDAs submitted and under FDA review, alongside reiterating key pipeline milestones and reporting financial performance.

Nuvalent has submitted a New Drug Application to the FDA for neladalkib, targeting advanced ALK-positive non-small cell lung cancer in pre-treated patients.

Nuvalent, Inc. announced significant pipeline advancements, reiterated key anticipated milestones, and reported fourth quarter and full year 2025 financial results, highlighting a robust cash position into 2029.

Nuvalent, Inc. reported its first-quarter 2026 financial results, highlighting continued progress in its clinical-stage biopharmaceutical pipeline with key regulatory milestones and trial updates.

Nuvalent, Inc. reports significant clinical progress for its oncology pipeline, including a completed NDA submission for zidesamtinib, amidst increasing net losses and a projected need for additional capital by 2028.

Nuvalent, Inc. announced positive pivotal data for zidesamtinib in ROS1-positive NSCLC and initiated a Phase 3 trial for neladalkib, while reporting increased net losses.

Nuvalent, Inc. announces its Q1 2025 financial results and provides updates on its clinical-stage programs, including zidesamtinib, neladalkib, and NVL-330.

Nuvalent, a clinical-stage biopharmaceutical company, released its Q3 2024 financial results and provided updates on its ongoing clinical trials for cancer therapies.

Nuvalent, a clinical-stage biopharmaceutical company, released its second quarter 2024 financial results, highlighting ongoing clinical trials and research and development activities.

Nuvalent, Inc. reports significant progress in its targeted oncology pipeline, including an FDA NDA acceptance for zidesamtinib and positive topline data for neladalkib, while continuing to incur substantial net losses.

Nuvalent's 2024 10-K filing highlights advancements in their clinical-stage cancer therapies and reaffirms their goal to launch their first approved product in 2026.

Nuvalent Inc., a clinical-stage biopharmaceutical company, has filed its 10-K report, detailing progress in its oncology drug pipeline and outlining plans for potential product approval by 2026.

James E Flynn and 7 others reported changes in beneficial ownership of Nuvalent, Inc. common stock on July 15, 2026.

Michael L. Meyers, a Director of Nuvalent, Inc., reported multiple transactions in common stock on July 15, 2026.

Alexandra Balcom, Chief Financial Officer of Nuvalent, Inc., reported multiple transactions in common stock on July 15, 2026.

Sapna Srivastava, a Director of Nuvalent, Inc., reported multiple transactions in common stock on July 15, 2026.

Christy J. Oliger, a Director of Nuvalent, Inc., reported multiple transactions in common stock on July 15, 2026.

Ron Squarer, a Director of Nuvalent, Inc., reported multiple transactions in common stock on July 15, 2026.

Nuvalent, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 16, 2026, to elect directors, approve executive compensation, and ratify auditor appointments.

Nuvalent, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on June 18, 2025, with key voting items including the election of directors, executive compensation approval, and ratification of KPMG LLP as the independent accounting firm.

Nuvalent, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 18, 2025, to vote on director elections, executive compensation, and auditor ratification.

Nuvalent, Inc. announces its 2024 Annual Meeting of Stockholders to be held on June 12, 2024, outlining key proposals for shareholder voting.

Nuvalent, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on June 12, 2024, to vote on director elections, executive compensation, and auditor ratification.

Deerfield Management and affiliated entities have filed a Schedule 13G, reporting 0% beneficial ownership of Nuvalent, Inc. Class A common stock as of July 15, 2026.

FMR LLC, through its subsidiaries, has disclosed beneficial ownership of 1.9% of Nuvalent Inc.'s Class A Common Stock as of June 30, 2026.

FMR LLC, through its subsidiaries, has reported beneficial ownership of 12.6% of Nuvalent Inc.'s Class A Common Stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Nuvalent Inc. following an internal realignment.

Deerfield Management Company and its affiliates, along with James E. Flynn, have reported a combined beneficial ownership of 24.21% in Nuvalent, Inc.'s Class A common stock.

BlackRock, Inc. has reported a beneficial ownership of 5.0% of Nuvalent, Inc.'s Class A Stock, totaling 3,338,764 shares.